Alps Advisors Inc. Has $498,000 Stake in Atara Biotherapeutics, Inc. (ATRA)
Alps Advisors Inc. lifted its holdings in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 14.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 30,095 shares of the biotechnology company’s stock after acquiring an additional 3,821 shares during the quarter. Alps Advisors Inc. owned 0.10% of Atara Biotherapeutics worth $498,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. Voya Investment Management LLC boosted its stake in Atara Biotherapeutics by 16.2% in the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 1,651 shares during the period. State of Wisconsin Investment Board acquired a new position in Atara Biotherapeutics in the second quarter valued at approximately $252,000. The Manufacturers Life Insurance Company boosted its stake in Atara Biotherapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock valued at $285,000 after acquiring an additional 1,369 shares during the period. American International Group Inc. boosted its stake in Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock valued at $294,000 after acquiring an additional 948 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in Atara Biotherapeutics by 2.9% in the second quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock valued at $304,000 after acquiring an additional 610 shares during the period. 82.95% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Alps Advisors Inc. Has $498,000 Stake in Atara Biotherapeutics, Inc. (ATRA)” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/11/19/alps-advisors-inc-has-498000-stake-in-atara-biotherapeutics-inc-atra.html.
Several brokerages have recently issued reports on ATRA. Jefferies Group LLC reiterated a “buy” rating and set a $30.00 price objective on shares of Atara Biotherapeutics in a research report on Thursday, August 31st. Zacks Investment Research cut Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 28th. ValuEngine raised Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $20.00 target price on shares of Atara Biotherapeutics in a report on Friday, October 6th. Finally, Canaccord Genuity reissued a “buy” rating and set a $47.00 target price on shares of Atara Biotherapeutics in a report on Monday, September 11th. Three analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $24.40.
Atara Biotherapeutics, Inc. (NASDAQ ATRA) opened at $14.60 on Friday. Atara Biotherapeutics, Inc. has a twelve month low of $11.80 and a twelve month high of $23.00.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.05). sell-side analysts forecast that Atara Biotherapeutics, Inc. will post -4 EPS for the current fiscal year.
In other news, EVP Christopher Haqq sold 6,000 shares of the business’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $15.30, for a total transaction of $91,800.00. Following the transaction, the executive vice president now directly owns 349,305 shares in the company, valued at approximately $5,344,366.50. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Isaac E. Ciechanover sold 4,400 shares of the company’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $15.02, for a total transaction of $66,088.00. Following the completion of the sale, the chief executive officer now owns 737,767 shares of the company’s stock, valued at $11,081,260.34. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,388 shares of company stock worth $733,884. Corporate insiders own 16.20% of the company’s stock.
Atara Biotherapeutics Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.